Dec 3 (Reuters) - AstraZeneca has signed a deal worth up to $247 million with U.S. firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. (Reporting by Shivani Tanna in Bengaluru; Editing by William Mallard)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,988 GBX | -0.32% | +9.52% | +13.09% |
Apr. 26 | ASTRAZENECA : DZ Bank sticks Neutral | ZD |
Apr. 26 | ASTRAZENECA : UBS keeps a Sell rating | ZD |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
11,988 GBX | -0.32% | +9.52% | 231B | ||
4.58 USD | +2.81% | -3.98% | 518M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.09% | 231B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B | |
-11.77% | 144B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca ties up with AI biologics company to develop cancer drug - FT